Screener / SEC EDGAR /CIK 0001551306 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

Progyny, Inc. PGNY

Compare with peers Embed
The 10-K against last year's

78 changes: 7 added, 7 removed, 61 reworded, 3 quiet changes

10-K Feb 27, 2026 vs Mar 3, 2025

10-K 0001551306-26-000020 (Feb 27, 2026) vs 10-K 0001551306-25-000040 (Mar 3, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

200 paragraphs · 4 new · 47 reworded · 5 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 96 · 43% changed Every version of it
•changes in tax laws, tax treaties, or regulations or the interpretation of them (such as the Inflation Reduction One Big Beautiful Bill Act, which, among other changes, introduced a 15% corporate minimum tax on makes permanent the immediate expensing of certain United States corporations domestic research and a 1% excise tax on certain stock redemptions by United States corporations); development costs and 100% bonus depreciation for eligible property);
Paragraph 49 · 42% changed Every version of it
We have experienced significant growth since the launch of our fertility benefits solution in 2016. Revenue Our future revenue and our client base may not grow at the same rates they historically have, or they may decline in the future. Our future growth will depend, in part, on our ability to: at all.
Paragraph 88 · 28% changed Every version of it
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us, and our competitive position would be harmed. Third parties may allege that our products and services, or the conduct of our business, infringe, misappropriate or otherwise violate such third party’s intellectual property rights. Even if such claims are without merit, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages or seek a costly license if we are found to be infringing, misappropriating, or otherwise violating a third party’s intellectual property rights. If we are unable to enter into a license on acceptable terms or at all, we could be forced to cease some aspect of our business operations or be forced to redesign our products or services so that we no longer infringe a third-party's intellectual property rights, which may result in significant cost and delay to us or which redesign could be technically infeasible. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our employees and management from their normal responsibilities.
Paragraph 71 · 26% changed Every version of it
The seasonality of our business could create cash flow management risks if we do not adequately anticipate and plan for periods of comparatively decreased cash flow, which could negatively impact our ability to execute on our strategy, which in turn could harm our results of operations. Accordingly, our results for any particular quarter may vary for a number of reasons, and we caution investors to evaluate our quarterly results in light of these factors.
Paragraph 63 · 25% changed Every version of it
Our estimates of the market opportunity for our services are based on the assumption that the purpose-built, data-driven and disruptive fertility benefits platform with the Smart Cycle plan design we offer will continue to be attractive to employers. Employers may pursue alternatives or may not see the value in providing enhanced fertility-related coverage and services to their employees. In addition, we believe we are helping to expand the size of the fertility market as we enhance demand and increase awareness for fertility benefits. If these assumptions prove inaccurate, or if the increase in awareness of fertility benefits attracts potential competitors to enter the market and results in greater competition, our business, financial condition and results of operations could be adversely affected.
Paragraph 34 · 25% changed Every version of it
We went live with our fertility benefits solution in 2016, Progyny Rx in 2018 and more recently with our newer solutions. As a result of our limited operating history with our current platform of solutions, as well as a limited amount of time serving a majority of our client base, our ability to accurately forecast our future results of operations is limited and subject to a number of uncertainties, including our ability to plan for and model future growth. Our historical revenue growth should not be considered indicative of our future performance. Further, in future periods, our revenue growth could slow or decline for a number of reasons, including slowing demand for our solutions and fertility and women's health benefits in general, change in utilization trends by our members, general economic slowdown, an increase in unemployment rates, increased competition, changes in healthcare trends and regulations, changes to science relating to the fertility market, a decrease in the growth of the fertility market, or our failure to anticipate and adapt to changing market trends and to take advantage of growth opportunities. If our assumptions regarding these risks and uncertainties and our future revenue growth are incorrect or change, or if we do not address these risks effectively, our operating and financial results could differ materially from our expectations, and our business could suffer.
Paragraph 101 · 24% changed Every version of it
We currently file tax returns in certain states. There is a risk that certain state tax authorities, where we do not currently file a tax return, could assert that we are liable for state and local taxes based on income or gross receipts allocable to such states. States are becoming increasingly aggressive in asserting a nexus for state tax purposes. We could be subject to state and local taxation, including penalties and interest attributable to prior periods, if a state tax authority where we do not currently file a state tax return successfully asserts that our activities give rise to a taxable nexus. Such tax assessments, penalties and interest may adversely affect our results of operations.
Paragraph 123 · 24% changed Every version of it
As we continue to execute on our growth strategy, we may be subject to new laws, regulations, and other requirements. We announced that we anticipate offering our fertility solution to large group fully insured employers, which will subject us to additional laws, regulations and other requirements. We expect to devote a significant amount of management time and resources related to ensuring regulatory compliance in connection this new offering, and such compliance costs will be ongoing and may increase in the future. We are unable to predict how new legislation, regulation, judicial action or executive action will ultimately impact the healthcare industry at large or our business and our relationships with existing and future clients, insurance carriers, and healthcare providers in particular. We also cannot predict the timing or impact of any future rule making, court decisions or other changes in law. If we are unable to comply with new laws and regulations or provide adequate assistance to our clients who may be subject to such laws or regulations, or if such changes impact our current business model and operations, we may be exposed to litigation or other government action and our business, financial condition and results of operations may be adversely impacted.

MD&A

86 paragraphs · 3 new · 38 reworded · 2 gone · 10-K Feb 27, 2026 against Mar 3, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 54 · 36% changed
Interest and other income, net increased decreased by $7.2 $5.6 million or 36%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, primarily due to increases 2024, as higher interest income was more than offset by a decrease in investment income and an increase in interest income. expense.
Paragraph 52 · 35% changed
General and administrative expense increased by $4.8 $25.1 million, or 4%, 21%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023. 2024. This increase was primarily due to a $6.0 $16.5 million increase in personnel-related costs costs, which included an increase of $5.0 million in stock-based compensation expense, attributable to incremental head count, count and executive severance costs, a $4.1 million increase in bad debt expense driven by our revenue growth, and a $2.3 $4.5 million net increase in other related general and administrative expenses, partially offset by expenses. Stock-based compensation expense included $7.7 million of executive severance costs in the year ended December 31, 2025 mainly attributable to the accelerated vesting of awards upon the termination of an executive in December 2025. Other related general and administrative expense also included a $3.5 benefit of $2.1 million decrease in bad debt expense. the year ended December 31, 2025 related to employee retention credit refunds.
Paragraph 19 · 33% changed
(3)Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.
Paragraph 17 · 30% changed
(1)Represents the number of ART cycles performed, including IVF with a fresh embryo transfer, IVF freeze all cycles/embryo banking, frozen embryo transfers and egg freezing. Includes ART cycles performed in the first half of 2025 under the extended transition of care agreement with the large client who did not renew its service agreement.
Paragraph 68 · 26% changed
In February 2024, our Board of Directors authorized a share repurchase program of up to $100 million in shares of common stock. In May 2024, our Board of Directors authorized an additional share repurchase program of up to $100 million in shares of common stock. In August 2024, our Board of Directors authorized an additional share repurchase program of up to $100 million in shares of common stock. As of the year ended December 31, 2024, the share repurchase programs were completed, and no amounts remained available for repurchase under the program.
Paragraph 46 · 24% changed
Year Ended December 31, 2025 2024 2023 % Change (dollars in thousands) Cost of services $ 913,858 $849,799 8% Gross profit $304,484 $253,363 20% Gross margin 23.6% 21.7%
Paragraph 18 · 20% changed
(2)Represents the member utilization rate for all fertility and family building services, including but not limited to, ART cycles, initial consultations, IUIs and genetic testing. The utilization rate for all members includes all unique members (female and male) who utilize the benefit during that period while the utilization rate for female only includes only unique females who utilize the benefit during that period. For the purposes of calculating utilization rates in any given period, the results reflect the number of unique members utilizing the benefit for that period. Individual periods cannot be combined as member treatments may span multiple periods. Utilization for 2025 excludes activity under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement, as only members meeting certain criteria were eligible to use the benefit.
Paragraph 48 · 18% changed
Gross margin decreased 20 increased 190 basis points for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, 2024, primarily due to an increase in personnel-related costs ongoing efficiencies realized in the delivery of our care management services.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Accounting Policies138 words changed in this paragraph; it is 74% similar to last year's version.
Progyny’s contracts include the following sources of consideration, which are all variable: a per employee per month (‘‘PEPM’’) ("PEPM") administration fee (in most, but not all contracts) and a fixed rate per Smart Cycle. The PEPM administration fee is estimated using the expected value method and is allocated between the fertility benefits solution and the pharmacy benefits solution based on standalone selling price, estimated using an expected cost-plus margin method. The Company allocates the variable consideration related to the fixed rate per Smart Cycle meets the variable consideration allocation exception as the usage-based fees relate specifically to the Company's efforts to satisfy the performance obligation to provide services and is allocated to the distinct period during which the related services were performed as those fees relate specifically to the Company’s efforts to provide its fertility benefits solution to its clients in the period and represents the consideration the Company is entitled to for the fertility benefits services provided. As a result, the fixed rate per Smart Cycle is included in the transaction price and recognized in for the period in which the Smart Cycle is provided to the member. fertility benefits solution. Progyny’s contracts also include potential service level agreement refunds related to outcome-based service metrics. These service level refunds, which are determined based on results of a full plan year, if met, are based on a percentage of the PEPM fee paid by clients. In addition, certain client contracts include service level agreement refunds related to financial metrics for a full plan year. The Company estimates the variable consideration related to the total PEPM administration fee, less estimated refunds related to for service level agreements, agreement refunds using the expected value method and recognizes the amounts allocated to the fertility benefits solution ratably over the contract term. Progyny’s estimates of service level agreement refunds, refunds have not historically resulted in significant adjustments to the transaction price. There is no constraint on variable consideration within Progyny's fertility benefits contracts.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001551306-26-000020 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001551306-25-000040

Risk Factors136 words changed in this paragraph; it is 69% similar to last year's version.
To increase our revenue, we must continue to attract new clients. Our ability to do so depends in large part on the success of our sales and marketing efforts and our ability to attract industry leaders in diversified sectors, which could prompt others in the same sectors to follow suit in order to remain competitive. Potential clients may seek out other options; therefore, we must demonstrate that our solutions are valuable and superior to alternatives. If we fail to provide high-quality solutions and convince clients of the benefits of our model and value proposition, we may not be able to attract new clients. The market for our solutions could decline or grow more slowly than we expect, including due to general economic conditions, high unemployment rates, reductions in workforce or employee attrition, impacts related to epidemics, pandemics, and outbreaks of contagious diseases, a decrease in business investments, including spending on employee benefits, and other factors. If the market for our solutions declines or grows more slowly than we expect, or if the number of clients that contract with us for our solutions declines or fails to increase as we expect, our financial results could be adversely impacted. As the markets in which we participate mature, fertility solutions and services evolve and competitors begin to enter the market and introduce differentiated solutions or services that are perceived to compete with our solutions, particularly if such competing solutions are adopted by an industry leader in a particular sector, our ability to sell our solutions could be impaired. As a result of these and other factors, we may be unable to attract new clients, which would have an adverse effect on our business, financial condition and results of operations.

Source: Item 1A, 10-K 0001551306-26-000020 vs Item 1A, 10-K 0001551306-25-000040

MD&A123 words changed in this paragraph; it is 57% similar to last year's version.
Net cash provided by operating activities was $188.8 $210.2 million for the year ended December 31, 2023, 2025, primarily consisting of net income of $62.0 $58.5 million adjusted for certain non-cash items, which included $122.6 includes $131.9 million of stock-based compensation expense, $19.9 $20.5 million of bad debt expense, $3.7 $8.1 million of deferred tax expense, and $2.3 benefit, $4.9 million of depreciation and amortization. amortization expense, $0.9 million of net accretion of discounts on marketable securities, $0.4 million of non-cash interest expense, and $0.1 million of loss on disposal of property and equipment. Changes in operating assets and liabilities resulted in cash provided by operating activities from an increase in accounts payable of $28.8 million and accrued expenses and other current liabilities of $0.4 million, that was partially offset by cash used in operating activities from an increase in prepaid expenses and other current assets of $22.9 million $11.9 million, other noncurrent assets and liabilities of $9.3 million, and accounts receivable of $21.7 million, partially $5.1 million. These changes were a result of the impact of revenue growth and our operating results as well as the timing of cash collections and payments to third parties, including $55.5 million of cash paid for income taxes, net of refunds for the year ended December 31, 2025.

Source: Item 7, 10-K 0001551306-26-000020 vs Item 7, 10-K 0001551306-25-000040

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of PGNY's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Mar 3, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
The global economy has also been impacted by geopolitical tensions. There is currently significant uncertainty about future trade relationships between the United States and various other countries. Further escalation of specific trade tensions, or more broadly in global trade conflicts, could materially and adversely affect the Company’s business and operations. The U.S. government and other governments may impose tariffs on certain pharmaceutical drugs and their components that may impact pharmaceutical imports into the United States, and we, our customers, suppliers, and our pharmacy program partners may then become subject to additional tariffs and adverse business impacts. If we are not successful in mitigating the impact of tariffs, trade barriers, and other geopolitical disruptions, our business, financial condition and results of operations may be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We use, and may in the future continue to use, artificial intelligence (“AI”), including generative AI, in connection with our business and operations, including for internal operational and productivity improvement business purposes. There are significant risks involved in utilizing AI, the development and use of which is still in its early stages, and no assurance can be provided that such use will enhance our business or operations or result in our business or operations being more efficient or profitable. AI models and algorithms, and the data, prompts and other material or content on which it relies, as well as the output thereof, could be flawed, insufficient, of poor quality, reflect unwanted forms of bias, or contain other errors or inadequacies, any of which may not be easily detectable. AI has also been known to produce false or “hallucinatory” inferences or outputs, and AI can subject users to new or heightened legal, regulatory, ethical, operational, reputational or other challenges. Inappropriate or controversial data practices by developers and end-users, or other factors adversely affecting public opinion of AI, could impair the acceptance of AI solutions. If the AI solutions that we use are or are perceived to be deficient, inaccurate or controversial, we could suffer operational inefficiencies, competitive harm, legal liability, brand or reputational harm, or other adverse impacts on our business, operations and financial results. The use of AI solutions by companies has also resulted in, and may in the future result in, failures, interruptions and security breaches of their information technology systems and data privacy violations that implicate the personal data or confidential information of users of such AI solutions. If any of our employees, contractors, vendors or service providers use any third-party AI solutions in connection with the services they provide to us, it may lead to the inadvertent disclosure of our confidential information, including personal information of our clients and members, which may impact our ability to secure such information, or adequately protect and enforce our intellectual property rights, harming our competitive position and business. Further, any content created by us using generative AI may not be subject to copyright protection which may adversely affect our intellectual property rights in, or ability to commercialize or use, any such content.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Regulation of AI is rapidly evolving worldwide and may change the competitive landscape of our and many other industries. AI is also an area of increased focus for legislators and regulators as this emerging technology develops. The technologies underlying AI and its uses are already subject to a variety of laws and regulations, including intellectual property, data privacy and security, consumer protection, competition, and equal opportunity laws and regulations, and are expected to be subject to increased regulation and new laws or new applications of existing laws and regulations. It is possible that we will not be able to anticipate how to respond to these rapidly evolving frameworks, and we could be required to expend resources to adjust our offerings in certain jurisdictions if the legal frameworks are inconsistent across jurisdictions. If we do not have sufficient rights to use the models, algorithms, data, prompts or other material or content on which our AI solutions rely, or the output thereof, we could also incur liability through the violation of applicable laws and regulations, third-party intellectual property, privacy or other rights, or contracts to which we are a party. Furthermore, because AI technology itself is highly complex, costly, and rapidly developing, it is not possible to predict all of the legal, operational or technological risks that may arise relating to the use of AI.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us, and our competitive position would be harmed.
Read it in 10-K Mar 3, 2025 at sec.gov
RemovedRisk Factors
In addition, specialty pharmacies could face supply chain issues or regulatory delays impacting the availability or distribution of certain fertility medication requiring drug substitutions that could result in higher medical costs or
Read it in 10-K Mar 3, 2025 at sec.gov
Show the other 33
RemovedRisk Factors
“anti-ESG” policies, legislation, or initiatives or issuing related legal opinions, as well as executive actions in response to ESG-related initiatives in the private sector. Such anti-ESG-related policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedRisk Factors
Senate For example, on February 3, 2026, the Consolidated Appropriations Act of 2026 was signed into law and House of Representatives proposed a number of bills includes PBM reforms that would, among other things, require PBMs to submit disclose information on their costs, fees and rebates; require 100% of the rebates to be passed on to consumers; and/or and impose rebates other disclosure, reporting and audit requirements on manufacturers that choose to increase their drug prices at a rate that exceeds the inflation rate. PBMs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In addition, in recent years, “anti-ESG” sentiment has gained momentum across the U.S., with several states, Congress, and most recently, the new U.S. presidential administration proposing or enacting “anti-ESG” policies, legislation, or initiatives or issuing related legal opinions, as well as executive actions in response to ESG-related initiatives in the private sector.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Such changes may also impact our ability to offer our products in the same manner to our clients, which may require us to change, reduce, or terminate portions of our business, disqualify us from serving clients in certain states or clients that do business with government entities, or to refund some or all of our service fees or otherwise compensate our clients.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In June 2022, July 2024, the FTC announced an inquiry into the role of released its interim staff report on PBMs and stated its intent to closely scrutinize the impact of PBM rebates and fees on patients and payers.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Although President Biden issued executive orders and federal agencies have issued guidance intended to protect access to reproductive healthcare services, the The enactment of certain state laws restricting abortion care and other changes in laws, or in interpretation of laws through court decisions, affecting fertility benefits may conflict with, and ultimately limit, the covered benefits offered by a company to its employees and the types of fertility treatment services available at provider clinics.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
A number of these proposed laws would require In certain states, PBMs are required to submit annual file transparency reports or otherwise disclose contractual arrangements with health plans or health insurance issuers or allow and regulators have begun to conduct audits of PBM operations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
If the information we publish is considered untrue, we may be subject to claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences, including, costs of defending against litigation or settling claims and loss of existing and future clients.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We have also expanded our offerings to include preconception, maternity pregnancy and postpartum and postpartum, menopause and midlife care care, benefit and leave navigation and parent and child wellbeing solutions.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Separately, although ERISA generally preempts state laws that would otherwise apply to ERISA plans, the recent Supreme Court ruling in Rutledge v. rulings continue to clarify ERISA preemption as it relates to PBMs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Negative conditions in the general economy in the United States and elsewhere, including conditions resulting from changes in gross domestic product growth, financial and credit market fluctuations, inflation, consumer confidence, international trade relations, tariffs, export controls and other trade barriers, global trade wars or domestic preferences, geopolitical conflict, political turmoil, natural catastrophes, epidemics, pandemics or outbreaks of contagious diseases, warfare and terrorist attacks, could cause a decrease in business investments, including spending on employee benefits, and negatively affect the growth of our business.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We continue to expand our women's health and family building solutions to include pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. While these offerings represent strategic areas of investment, they were not a significant portion of our revenue for the years ended December 31, 2025 and 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On July 1, 2025, we entered into a revolving credit facility (the “Facility”) pursuant to a Credit Agreement (the “Credit Agreement”) with the lenders and issuing banks, party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swing line lender. The Credit Agreement makes available a maximum aggregate amount of $200 million, subject to customary borrowing conditions, until its maturity on July 1, 2030. We are in compliance with all financial covenants under the Credit Agreement as of December 31, 2025. As of the date of this filing, no amounts were drawn under the Facility. Refer to Note 9 to the Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In November 2025, our Board of Directors authorized a share repurchase program of up to $200 million in shares of common stock (the “November 2025 share repurchase program”). Repurchases under the November 2025 share repurchase program may be made in the form of open market repurchases, including through plans complying with Rule 10b5-1 under the Exchange Act, depending on stock price, market conditions, and other factors, as determined by the Company. There can be no assurance as to the total number of shares that will be repurchased by the Company under the November 2025 share repurchase program.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
personnel costs, including stock-based compensation expense, and other costs necessary to deliver our care management services will continue to grow as we continue to add clients and their associated members.
Read it in 10-K Mar 3, 2025 at sec.gov
RewordedMD&A
Net cash used in financing activities was $309.9 $99.4 million for the year ended December 31, 2024, 2025, consisting of $300.3 $81.7 million of repurchases of common stock under the 2024 Share Repurchase Programs, November 2025 share repurchase program, inclusive of $0.4 $0.1 million in trading fees and fees, payments of $12.0 $15.8 million for employee taxes related to the net settlement of equity awards, and $3.1 million of issuance costs related to the Facility, partially offset by $1.1 million in proceeds from stock option exercises and $1.3 million in proceeds from contributions to our employee stock purchase plan. plan and $0.1 million in proceeds from stock option exercises.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
This increase was primarily due to a $6.0 $16.5 million increase in personnel-related costs costs, which included an increase of $5.0 million in stock-based compensation expense, attributable to incremental head count, count and executive severance costs, a $4.1 million increase in bad debt expense driven by our revenue growth, and a $2.3 $4.5 million net increase in other related general and administrative expenses, partially offset by a $3.5 million decrease in bad debt expense. expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 (in thousands) Cash Net cash provided by operating activities $ 210,192 $ 179,105 $ 188,814 Cash Net cash (used in) provided by (used in) investing activities (159,013) 195,792 (200,525) Cash Net cash used in financing activities (99,362) (309,880) (11,072) Effect of exchange rate changes on cash, cash equivalents, and restricted cash equivalents $ 1 $ 62 1 Net (decrease) increase (decrease) in cash, cash equivalents, and restricted cash equivalents $ (48,121) $ 65,018 $ (22,782)
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
(3)Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Interest and other income, net increased decreased by $7.2 $5.6 million or 36%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, primarily due to increases 2024, as higher interest income was more than offset by a decrease in investment income and an increase in interest income. expense.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Net cash provided by operating activities was $179.1 $210.2 million for the year ended December 31, 2024, 2025, primarily consisting of net income of $54.3 $58.5 million adjusted for certain non-cash items, which included $128.1 includes $131.9 million of stock-based compensation expense, $16.4 $20.5 million of bad debt expense, $10.5 $8.1 million of deferred tax benefit, $3.2 $4.9 million of depreciation and amortization, $2.1 amortization expense, $0.9 million of net accretion of discounts on marketable securities, $0.4 million of non-cash interest expense, and $1.4 $0.1 million of loss on disposal of property and equipment.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
This increase in cost of services was also attributable to an increase in personnel-related costs primarily due as higher costs attributable to incremental headcount as well as an $2.3 million increase head count were partially offset by a decrease in stock-based compensation expense. expense of $1.5 million.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, 2025, we recorded a provision for income taxes of $28.9 $36.9 million, as compared to a provision for income taxes of $8.7 $28.9 million for the year ended December 31, 2023, 2024, primarily due to a higher operating profit as well as and a decrease in tax benefits for equity compensation. compensation in the current year period.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
In February 2022, we entered into a lease agreement for leases commencing in February 2023 and March 2025 for additional space in our corporate offices in New York, New York, consisting of a 24,099 square foot office and a 21,262 square foot office, and also for continued occupancy of the 25,212 square foot office after the expiration of the current sublease. respectively.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
A discussion of the fiscal year ended December 31, 2023 2024 as compared to the year ended December 31, 2022 2023 has been reported previously in our Annual Report on Form 10-K for the year ended December 31, 2023 2024, which was filed with the SEC on February 29, 2024 March 3, 2025 (File No. 001-39100) under the heading “Management's Discussion and Analysis of Financial Condition and Results of Operations - Comparison of Years Ended December 31, 2023 2024 and 2022.” 2023.”
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
This increase was primarily due to a $3.5 $5.8 million increase in personnel-related costs attributable to incremental head count which included an increase in stock-based compensation expense, as well as expense of $0.2 million, and a $1.0 $2.4 million increase in other related sales and marketing expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
During the year ended December 31, 2024, 2025, we repurchased a total of 12,382,193 3,301,596 shares of common stock under the 2024 Share Repurchase Programs November 2025 share repurchase program at an average price per share of $24.22 $25.31 and a total cost of $300.3 $83.6 million, inclusive of $0.4 $0.1 million in trading fees.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesMD&A
We believe there is sufficient positive evidence to conclude that it is more likely than not not, that substantially all the net deferred tax assets were realizable as of December 31, 2024. 2025.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PGNY/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.